Caveolin-3 regulates myostatin signaling. Mini-review

Acta Myologica

Volumn 27, Issue JULY, 2008, Pages 19-24

  Ohsawa, Y ^a   Okada, T ^a   Kuga, A ^a   Hayashi, S ^a   Murakami, T ^a   Tsuchida, K ^b   Noji, S ^c   Sunada, Y ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Autosomal dominant rippling muscle disease (AD RMD); Caveolin 3; Limb girdle muscular dystrophy 1C (LG MD1C); Myostatin; Transforming growth factor (TGF )

Indexed keywords

ACTIVIN RECEPTOR 2; ALPHA SARCOGLYCAN; CAVEOLIN 1; CAVEOLIN 2; CAVEOLIN 3; CHOLESTEROL; CYTOKINE RECEPTOR ANTAGONIST; FOLLISTATIN; FOLLISTATIN RELATED PROTEIN; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; MYOSTATIN; MYOSTATIN ANTIBODY; MYOSTATIN VACCINE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; PARVOVIRUS VECTOR; PROTEIN P21; RAS PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL DOMINANT RIPPLING MUSCLE DISEASE; CAVEOLA; CELL MEMBRANE; CONFERENCE PAPER; DRUG TARGETING; GENE MUTATION; HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY; MUSCLE DISEASE; MUSCLE MASS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; VIRAL GENE THERAPY;

ANIMALS; CAVEOLIN 3; DISEASE MODELS, ANIMAL; HUMANS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MUTATION; MYOSTATIN; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 51649089683     PISSN: 11282460     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. Parton RG. Caveolae-from ultrastructure to molecular mechanism. Nat Rev Mol Cell Biol 2003;4:162-7.
2. Parton RG, Hanzal-Bayer M, Hancock JF. Biogenesis of caveolae: a structural model for caveolin-induced domain formation. J Cell Sci 2006;119:787-96.
3. Parton GP, Simonds K. The multiple faces of caveolae. Nat Rev Mol Cell Biol 2007;8:185-94.
4. Monier S, Parton RG, Vogel F, et al. VIP21-caveolin, a membrane protein constituent of the caveolar coat, oligomerizes in vivo and in vitro. Mol Biol Cell 1995;6:911-27.
5. Razani B, Schlegel A, Lisanti MP. Caveolin proteins in signaling, oncogenic transformation and muscular dystrophy. J Cell Sci 2000;113:2103-9.
6. Galbiati F, Razani B, Lisanti MP. Emerging themes in lipid rafts and caveolae. Cell 2001;106:403-11.
7. Couet J, Li S, Okamoto T, et al. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J Biol Chem 1997;272:6523-33.
8. Minetti C, Sotgia F, Bruno C, et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 1998;18:365-8.
9. Betz RC, Schoser BG, Kasper D, et al. Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease. Nat Genet 2001;28:218-9.
10. Galbiati F, Volonte D, Minetti C, et al. Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the Golgi complex. J Biol Chem 1999;274:25632-41.
11. Sunada Y, Ohi H, Hase A, et al. Transgenic mice expressing mutant caveolin-3 show severe myopathy associated with increased nNOS activity. Hum Mol Genet 2001;10:173-8.
12. Kubisch C, Schoser BG, von Düring M, et al. Homozygous mutations in caveolin-3 cause a severe form of rippling muscle disease. Ann Neurol 2003;53:512-20.
13. Smythe GM, Eby JC, Disatnik MH, et al. A caveolin-3 mutant that causes limb girdle muscular dystrophy type 1C disrupts Src localization and activity and induces apoptosis in skeletal myotubes. J Cell Sci 2003;116:4739-49.
14. Sotgia F, Bonuccelli G, Minetti C, et al. Phosphofructokinase muscle-specific isoform requires caveolin-3 expression for plasma membrane recruitment and caveolar targeting: implications for the pathogenesis of caveolin-related muscle diseases. Am J Pathol 2003;163:2619-34.
15. Liu J, Aoki M, Illa I, et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 1998;20:31-6.
16. Matsuda C, Hayashi YK, Ogawa M, et al. The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle. Hum Mol Genet 2001;10:1761-6.
17. Bansal D, Miyake K, Vogal SS, et al. Defective membrane repair in dystrophin-deficient muscular dystrophy. Nature 2003;423:168-72.
18. Hernández-Deviez DJ, Martin S, Laval SH, et al. Aberrant dysferlin trafficking in cells lacking caveolin or expressing dystrophy mutants of caveolin-3. Hum Mol Genet 2006;15:129-42.
19. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387:83-90.
20. Zimmers TA, Davies MV, Koniaris LG, et al. Induction of cachexia in mice by systemically administered myostatin. Science 2002;296:1486-8.
21. Massagué J. TGF-beta signal transduction. Annu Rev Biochem 1998;67:753-91.
22. Thies RS, Chen T, Davies MV, et al. GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding. Growth Factors 2001;18:251-9.
23. Hill JJ, Davies MV, Pearson AA, et al. The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem 2002;277:40735-41.
24. Tsuchida K. Activins, myostatin and related TGF-beta family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr Drug Targets Immune Endocr Metabol Disord 2004;4:157-66.
25. Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 2001;98:9306-11.
26. Rebbapragada A, Benchabane H, Wrana JL, et al. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol Cell Biol 2003;23:7230-42.
27. Ríos R, Fernández-Nocelos S, Carneiro I, et al. Differential response to exogenous and endogenous myostatin in myoblasts suggests that myostatin acts as an autocrine factor in vivo. Endocrinology 2004;145:2795-803.
28. Thomas M, Langley B, Berry C, et al. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J Biol Chem 2000;275:40235-43.
29. Bogdanovich S, Krag TO, Barton ER, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002;420:418-21.
30. Tang L, Yan Z, Wan Y, et al. Myostatin DNA vaccine increases skeletal muscle mass and endurance in mice. Muscle Nerve 2007;36:342-8.
31. Bogdanovich S, Perkins KJ, Krag TO, et al. Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J 2005;19:543-9.
32. Nakatani M, Takehara Y, Sugino H, et al. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. FASEB J 2007 (in press).
33. Parsons SA, Millay DP, Sargent MA, et al. Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. Am J Pathol 2006;168:1975-85.
34. Bartoli M, Poupiot J, Vulin A, et al. AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency. Gene Ther 2007;14:733-40.
35. Razani B, Zhang XL, Bitzer M, et al. Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J Biol Chem 2001;276:6727-38.
36. Zhang XL, Topley N, Ito T, et al. Interleukin-6 regulation of transforming growth factor (TGF)-beta receptor compartmentalization and turnover enhances TGF-beta1 signaling. J Biol Chem 2005;280:12239-45.
37. Schwartz EA, Reaven E, Topper JN, et al. Transforming growth factor-beta receptors localize to caveolae and regulate endothelial nitric oxide synthase in normal human endothelial cells. Biochem J 2005;390:199-206.
38. Lee EK, Lee YS, Han IO, et al. Expression of Caveolin-1 reduces cellular responses to TGF-beta1 through down-regulating the expression of TGF-beta type II receptor gene in NIH3T3 fibroblast cells. Biochem Biophys Res Commun 2007;359:385-90.
39. Di Guglielmo GM, Roy CL, Goodfellow AF, et al. Distinct endocytic pathway regulates TGF-beta receptor signaling and turnover. Nat Cell Mol Biol 2003;5:410-21.
40. Roy L, Wrana JL. Clathrin- and non-clathrin-mediated endocytic regulation of cell signaling. Nat Rev Mol Cell Biol 2005;6:112-26.
41. Nohe A, Keating E, Underhill TM, et al. Dynamics and interaction of caveolin-1 isoforms with BMP-receptors. J Cell Sci 2005;118:643-50.
42. Ohsawa Y, Hagiwara H, Nakatani M, et al. Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition. J Clin Invest 2006;116:2924-34.
43. Nishi M, Yasue A, Nishimatu S, et al. A missense mutant myostatin causes hyperplasia without hypertrophy in the mouse muscle. Biochem Biophys Res Commun 2002;293:247-51.
44. Lee SJ, Reed LA, Davies MV, et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 2005;102:18117-22.
45. De Caestecker M. The transforming growth factor-beta superfamily of receptors. Cytokine Growth Factor Rev 2004;15:1-11.
46. Lee SJ. Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS ONE 2007;2:e789.
47. Hnasko R, Lisanti MP. The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol Interv 2003;3:445-64.
48. Sotgia F, Williams TM, Schubert W, et al. Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am J Pathol 2006;168:292-309.
49. Wang XM, Zhang Y, Kim HP, et al. Caveolin-l: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med 2006;203:2895-906.
50. Verma S, Slutsky AS. Idiopathic pulmonary fibrosis - new insights. N Engl J Med 2007;356:1370-2.